Our staff will be delivering numerous presentations and abstracts at the upcoming 2014 American Academy of Neurology Annual Meeting in Philadelphia, Pa. Mayo Medical Laboratories representatives will also be available at booth #1700 in the exhibit hall to discuss:
- NEUROMYELITIS OPTICA: Aquaporin-4-IgG cell-binding assay offers increased sensitivity and specificity in diagnosis
- PARANEOPLASTIC DISORDERS: Expediting diagnosis of reversible autoimmune neurological disorders and cancer
- CHROMOSOMAL MICROARRAY: Utilizing more than 1.9 million copy number probes and approximately 750,000 single nucleotide polymorphism probes
- FRIEDREICH ATAXIA: Frataxin concentration to diagnose and monitor patients
- FRONTOTEMPORAL DEMENTIA (FTD) & AMYOTROPHIC LATERAL SCLEROSIS (ALS): C9orf72 molecular analysis
Mayo Clinic studies, involving thousands of patients, have found the cell-based aquaporin-4-IgG (AQP4-IgG) antibody assay to be more sensitive and specific than ELISA methods. The improved sensitivity and specificity of the AQP4-IgG test offered by Mayo Medical Laboratories will assist clinicians in distinguishing early stage NMO spectrum disorders from multiple sclerosis.
- Featured Topic: Neuromyelitis Optica (NMO) Spectrum Disorders
- Test Catalog: Neuromyelitis Optica (NMO)/Aquaporin-4-IgG Cell-Binding Assay: Serum | CSF
The Paraneoplastic Autoantibody Evaluation developed by Mayo Clinic Neuroimmunology Laboratory, is a patient-individualized, physician-directed consultation that aids the diagnosis of autoimmune disorders of brain, nerve, and muscle that reflect an immune response initiated by unsuspected cancer.
- Featured Topic: Paraneoplastic Autoimmune Neurological Disorders
- Featured Algorithm: Paraneoplastic Evaluation
- Test Catalog: Paraneoplastic Autoantibody Evaluation: Serum | Spinal Fluid
- Test Catalog: NMDA-Receptor Autoantibody by CBA: Serum | Spinal Fluid
Mayo Medical Laboratories offers a copy number plus single nucleotide polymorphism (SNP) chromosomal microarray test. To help clients gain a better understanding of this new test, we have compiled a list of frequently asked questions.
- Q&A: Chromosomal Microarray - Copy Number + SNP
- Test Catalog: Chromosomal Microarray, Congenital, Blood
Historically, Friedreich ataxia has been diagnosed by DNA-based testing. However, a molecular-based analysis does not effectively monitor treatment, is not amenable to multiplexing with other disease analytes, nor can it be efficiently utilized for population screening.
In contrast, a protein-based assay measuring concentration of frataxin is suitable for both diagnosis and treatment monitoring in individuals with Friedreich ataxia. This assay is also useful when the clinical suspicion of the disease is present and a clinician wants to include or exclude its possibility in a cost-effective manner.
- Hot Topic: Frataxin Protein Levels for the Assessment of Friedreich Ataxia
- Communiqué: Friedreich Ataxia - Diagnosis, Treatment, and Monitoring
- Featured Topic: Friedreich Ataxia - Protein-based Assay for Diagnosis and Treatment Monitoring
- Test Catalog: Friedreich Ataxia, Frataxin, Quantitative - Whole Blood | Blood Spot
Molecular analysis of c9orf72 can be useful for:
- Molecular confirmation of clinically suspected cases of c9frontotemporal dementia (FTD)/amyotrophic lateral sclerosis (ALS), FTD, or ALS
- Presymptomatic testing for individuals with a family history of c9FTD/ALS and a documented expansion in the C9orf72 gene
- Test Catalog: C9orf72 Hexanucleotide Repeat, Molecular Analysis
Autoantibody tests performed on serum and spinal fluid aid in the diagnosis of autoimmune disorders. Learn about Mayo Medical Laboratories’ comprehensive serological evaluations for:
- Myasthenia Gravis
- Paraneoplastic Disorders
- Featured Topic: Testing for Autoimmune Neurological Disorders
DPPX AUTOANTIBODY: FREQUENCY, CLINICAL ACCOMPANIMENTS AND OUTCOMES
S40: Platform Blitz: General Neurology II
Wednesday, April 30, 2014
4:00 – 5:45 p.m.
AQP4-IgG ASSAYS COMPARISON IN LABORATORY CLINICAL SERVICE
S63: Platform Session: Neuromyelitis Optica and Autoimmune Encephalitis
Thursday, May 1, 2014
4:00 – 5:45 p.m.
For a complete list of Mayo Clinic's 42 presentations, visit the 2014 AAN Annual Meeting website.